Literature DB >> 25588061

Tuscan consensus on the diagnosis, treatment and follow-up of moderate-to-severe psoriasis.

Francesca Prignano1, Lara Tripo2, Lauretta Amato3, Giovanni Bagnoni4, Laura Bartoli5, Silvio Battistini6, Mauro Bellini6, Luca Brandini3, Marzia Caproni2, Carla Cardinali7, Antonio Castelli8, Roberto Cecchi5, Gregorio Cervadoro9, Valentina Dini9, Michele Fimiani10, Olimpia Eberle4, Paolo Fabbri2, Giovanni Lo Scocco7, Patrizia Martini11, Franco Marsili12, Carlo Mazzatenta11, Maria C Niccoli7, Camilla Peccianti13, Michele Pellegrino10, Marco Romanelli9, Riccardo Sirna13, Franca Taviti7, Valter Volpi2, Nicola Pimpinelli2.   

Abstract

BACKGROUND: Psoriasis is traditionally defined as an inflammatory chronic-relapsing disease of the skin. As widely demonstrated, this disease is also associated with multiple comorbidities: arthropathy, inflammatory bowel disease, metabolic, cardiovascular, ocular and psychological disorders. The disease also has a significant impact on patients' quality of life, whose work ability decreases considerably with clear consequences for the social costs. Therefore, if we consider that in Tuscany, more than 100,000 people out of 3,672,202 suffer from psoriasis, it is of paramount importance focusing the attention on a rational model of clinical and therapeutic management of the disease. All the leading experts in Tuscany have come together with the aim of defining unanimously accepted regional guidelines for the diagnosis, treatment, follow-up and management of psoriasis, and of providing practical guidance/protocol on diagnosis, treatment, follow-up and management of special cases of moderate-to-severe plaque psoriasis.
METHODS: In a working group formed ad hoc, the main topics have been discussed and approved by plenary vote.
RESULTS: Diagnosis must include a proper general health condition overview, a careful evaluation of skin and joints, the assessment and management of other comorbidities and the definition of disease severity. With regards to the therapy the best time to start a systemic treatment, the therapeutic goal, the most appropriate drug and blood tests to be performed in case of moderate severe-psoriasis have been taken into account. During follow-up, proper monitoring of systemic therapy and its management in the long term has also been suggested. Eventually, the experts have addressed the problem of how to manage the disease in special conditions, such as during surgery, pregnancy, in children and in case of infections (HBV, HCV, HIV).
CONCLUSIONS: The main aim of this Consensus was to find agreement on the criteria for diagnosis, treatment and follow-up of psoriasis, shared by all the Dermatologic Therapy Units of Tuscany. A need to create an easier way for the patient to access specialized dermatology outpatient services, and to reduce the waiting list and costs related to the management of psoriasis has been stressed. Most importantly, during the Consensus all of the participants agreed on the central role of the patient, and on the need of a multidisciplinary management of the disease which requires communication among specialists and regional centers in order to build on existing experience.

Entities:  

Mesh:

Year:  2015        PMID: 25588061     DOI: 10.23736/S0392-0488.16.05005-7

Source DB:  PubMed          Journal:  G Ital Dermatol Venereol        ISSN: 0392-0488            Impact factor:   2.011


  2 in total

1.  Management of psoriatic patients in biologic treatment associated with infectious comorbidities.

Authors:  Bernardini Nicoletta; Narcisi Alessandra; Skroza Nevena; Ersilia Tolino; Daniela Colapietra; Mastroianni Claudio; Potenza Concetta
Journal:  Postepy Dermatol Alergol       Date:  2020-07-16       Impact factor: 1.837

2.  Methotrexate in the therapeutic pathway of patients with psoriasis. Analysis of clinical practice data and comparison with guidelines.

Authors:  Valeria Corazza; Francesco Cusano; Ornella De Pità; Luigi Rossi; G Giovanni Virno
Journal:  Dermatol Reports       Date:  2021-12-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.